Clinical trials: sponsored by Boehringer Ingelheim
Healthy
To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers
To investigate safety, tolerability and pharmacokinetics, following single doses of BI 443651
- Trial name
- NCT02706925
- Testing
- BI 443651
- Where
- Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Scleroderma, Systemic
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
Systemic Sclerosis (SSc) is a devastating disease of unknown etiology. Patients suffer from multiple organ fibrosis whereas lung fibrosis (interstitial lung disease, ILD) is one of the main driver for mortality.
- Trial name
- NCT02597933
- Testing
- Nintedanib
- Where
- 195 sites in United States, Argentina and 30 more
- Volunteers
- 580 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
Study to assess the long-term safety and effectiveness of Spiolto in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD) in real-world setting
- Trial name
- NCT02850978
- Testing
- Spiolto
- Where
- Japan
- Volunteers
- 1,335 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effectiveness of Triple Therapy in COPD
To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the Long-acting beta2-agonist - long-acting muscarinic antagonists-inhaled corticosteroids (LABA-LAMA-ICS) combination with…
- Trial name
- NCT03724877
- Testing
- Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS), Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)
- Where
- United Kingdom
- Volunteers
- 8,853 people
- Sponsor
- Boehringer Ingelheim
Asthma
BI 443651 Methacholine Challenge
The primary objective of this study is to investigate safety and tolerability of three consecutive administrations, 12 hours apart, at three different dose-levels of BI 443651 administered via oral inhalation in male and female…
- Trial name
- NCT03135899
- Testing
- BI 443651
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects
The objective of this study is to investigate the safety, tolerability, and pharmacokinetics of BI 443651 in male and female healthy volunteers and subjects with Cystic Fibrosis (CF).
- Trial name
- NCT02976519
- Testing
- BI 443651
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Asthma
Specific Use-Result of Spiriva Respimat® in Asthmatics
The study objective is to investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under real-world use
- Trial name
- NCT03188120
- Testing
- Spiriva Respimat
- Where
- Japan
- Volunteers
- 193 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets
The primary objective of the study is to investigate the relative bioavailability of Movalis capsules 15 mg (Test, T) versus Movalis tablets 15 mg (Reference, R).
- Trial name
- NCT03684265
- Testing
- Meloxicam Capsule (Test), Meloxicam Tablet (Reference)
- Where
- Russia
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Colorectal Neoplasms
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
The objective of this trial is to evaluate the safety and tolerability of BI 695502 in combination with leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) and as maintenance therapy (when applicable).
- Trial name
- INVICTAN®-3 (NCT02776683)
- Testing
- BI 695502, Avastin
- Where
- 46 sites in United States, Japan and 2 more
- Volunteers
- 123 people
- Sponsor
- Boehringer Ingelheim
Healthy
Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects
This trial will investigate the pharmacokinetics and safety of BI 695502 and to establish pharmacokinetic biosimilarity of BI 695502 compared to bevacizumab.
- Trial name
- NCT01608087
- Testing
- BI 695502, bevacizumab
- Where
- 2 sites in New Zealand
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hypertension
Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise
The aim of the observational study is to ascertain the degree of blood pressure control in the early-morning hours after 8 weeks of treatment with Telmisartan/Telmisartan+Hydrochlorothiazide and during 44 weeks of follow-up, in…
- Trial name
- NCT00946829
- Testing
- telmisartan
- Where
- 12 sites in Belgium, Canada and 10 more
- Volunteers
- 18,299 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)
Describe patient and physician assessed factors for patient well-being when treated with Pradaxa for stroke and embolism prevention in atrial fibrillation either compared to previous antithrombotic treatment (switcher)
- Trial name
- NCT02839746
- Where
- Spain
- Volunteers
- 671 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
PMS of Trazenta on the Long-term Use as Add-on Therapy
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as add-on therapy in patients with type 2 diabetes mellitus.
- Trial name
- NCT01904383
- Testing
- Trazenta
- Where
- Japan
- Volunteers
- 4,057 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Sequential Expansion of Comparative Effectiveness of Anticoagulants
This cohort study is the sequential expansion of the comparative effectiveness study of oral anticoagulants and plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database…
- Trial name
- NCT02081807
- Where
- United States
- Volunteers
- 221,228 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
OTIVACTO Spain Non Interventional Study
This is a self-controlled study design enrolling consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC.
- Trial name
- NCT02927795
- Where
- 79 sites in Spain
- Volunteers
- 257 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy
The purpose of the study is to measure changes in physical functioning in chronic obstructive pulmonary disease (COPD) patients being treated with Spiolto® Respimat® after approximately 6 weeks in routine clinical practice.
- Trial name
- OTIVACTO (NCT03003494)
- Testing
- Spiolto® Respimat®
- Where
- 28 sites in Italy
- Volunteers
- 306 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
The primary objective of the present study is to evaluate the effect of tiotropium + olodaterol fixed dose combination (FDC) compared to tiotropium monotherapy on the intensity of breathlessness during the 3min constant speed…
- Trial name
- NCT02853123
- Testing
- Tiotropium, Olodaterol
- Where
- 13 sites in Belgium, Canada and 2 more
- Volunteers
- 106 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as monotherapy in patients with type 2 diabetes mellitus and to assess baseline characteristics of patients with type 2 diabetes mellitus…
- Trial name
- NCT01650259
- Testing
- OAD, Trazenta
- Where
- Japan
- Volunteers
- 4,876 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis
The purpose of the present study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise…
- Trial name
- NCT02803580
- Where
- 18 sites in Italy
- Volunteers
- 209 people
- Sponsor
- Boehringer Ingelheim
Stroke, Secondary Prevention
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months.
- Trial name
- NCT02239120
- Testing
- optional ASA as comedication, ASA 100 mg
- Where
- 569 sites in United States, Argentina and 40 more
- Volunteers
- 5,390 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.